| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Nuclear Medicine Department of Diagnostic Radiology, Mayo Clinic, Rochester, Minnesota
Faculdade De Ciências Médicas, Universidade Nova De Lisboa, Lisbon, Portugal
Correspondence: For correspondence or reprints contact: Joseph C. Hung, PhD, Mayo Clinic, 200 First St. SW, Rochester, MN 55905.
ABSTRACT
Labeling leukocytes with 99mTc-exametazime is a validated technique for imaging infection and inflammation. A new radiolabeling technique has recently been described that enables leukocyte labeling with a more stable form of 99mTc-exametazime. A normal value study of stabilized 99mTc-exametazime-labeled leukocytes has been performed, including biodistribution and dosimetry estimates in normal subjects. Methods: Ten volunteers were injected with stabilized 99mTc-exametazime-labeled autologous leukocytes to study labeled leukocyte kinetics and dosimetry in normal subjects. Serial whole-body imaging and blood sampling were performed up to 24 h after injection. Cell-labeling efficiency and in vivo viability, organ dosimetry, and clearance calculations were obtained from the blood samples and imaging data as well as urine and stool collection up to 36 h after injection. Results: Cell-labeling efficiency of 87.5% ± 5.1% was achieved, which is similar to or better than that reported with the standard preparation of 99mTc-exametazime. In vivo stability of the radiolabeled leukocytes was also similar to in vitro results with stabilized 99mTc-exametazime and better than previously reported in vivo stability for nonstabilized 99mTc-exametazime-labeled leukocytes. Organ dosimetry and radiation absorbed doses were similar with a whole-body absorbed dose of 1.3 x 10-3 mGy/MBq. Urinary and fecal excretion of activity was minimal, and visual assessment of the images showed little renal parenchymal activity and no bowel activity up to 2 h after injection. Conclusion: Cell labeling and in vivo stability appear improved compared with the leukocytes labeled with the nonstabilized preparation of 99mTc-exametazime. There are advantages in more cost-effective preparation of the stabilized 99mTc-exametazime and an extended window for clinical usage, with good visualization of abdominal structures on early images. No significant increase in specific organ and whole-body dosimetry estimates was noted compared with previous estimates using nonstabilized 99mTc-exametazime-labeled leukocytes.
Key Words: stabilized 99mTc-exametazime • radiolabeled leukocytes • dosimetry • biodistribution • normal value study
This article has been cited by other articles:
|
|
 |
|
  R. J. Bennink, R. M. Thurlings, F. J. van Hemert, C. Voermans, S. E. Dohmen, B. L. van Eck-Smit, P. P. Tak, and E. Busemann-Sokole Biodistribution and Radiation Dosimetry of 99mTc-HMPAO-Labeled Monocytes in Patients with Rheumatoid Arthritis J. Nucl. Med., August 1, 2008; 49(8): 1380 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Hung, B. C. Iverson, K. A. Toulouse, and D. W. Mahoney Effects of Methylene Blue Stabilizer on In Vitro Viability and Chemotaxis of 99mTc-Exametazime-Labeled Leukocytes J. Nucl. Med., July 1, 2002; 43(7): 928 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Grüning, W.-G. Franke, P. D. Robins, I. Salazar, L. A. Forstrom, B. P. Mullan, and J. C. Hung Are Leukocytes Labeled with Stabilized 99mTc-HMPAO Becoming Activated During Labeling? J. Nucl. Med., April 1, 2001; 42(4): 685 - 686. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
